Leo Pharma's eczema drug for adolescents meets phase III trial targets
![Photo: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13397866.ece/ALTERNATES/schema-16_9/doc7i4asikfqo91ad22j4gz.jpg)
At the 2021 Fall Clinical Dermatology Conference, held virtually and from Las Vegas, pharmaceutical company Leo Pharma presented data from a new trial of its antibody treatment tralokinumab, sold under the brand name Adtralza, which is approved in the EU, the UK and Canada as a treatment for adults with moderate-to-severe atopic dermatitis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma strongly criticizes Danish Medicines Council
For subscribers